The Josep Carreras Leukaemia Research Institute, a member of Catalonia.health, is leading a new international alliance to accelerate the development of innovative diagnostic tools and therapeutic strategies for follicular lymphoma, one of the most common blood cancers. This disease accounts for between 20% and 25% of all non-Hodgkin lymphomas, with around 2.000 new cases diagnosed each year in Spain.
The consortium, known as ERADICATE Follicular Lymphoma and led by Dr Ari Melnick, Director of the Josep Carreras Institute, brings together leading research teams from Spain and the United States with the aim of gaining a deeper understanding of the biological complexity and unpredictable clinical course of the disease. The initiative seeks to improve therapeutic decision-making, reduce relapses and move towards a more personalised approach to the treatment of follicular lymphoma.
The project is supported by USD 6,5 million in funding over a five-year period, with the backing of Blood Cancer United® and the Institute for Follicular Lymphoma Innovation (IFLI). The collaboration integrates advanced technologies such as functional genomics, artificial intelligence and single-cell technologies, reinforcing the role of the Josep Carreras Institute as an international reference centre in blood cancer research.
“This global alliance allows us to move from knowledge to intervention at an unprecedented pace,” said Dr Ari Melnick, Director of the Josep Carreras Institute and of the ERADICATE alliance. “By closely connecting basic research, predictive diagnostics and translational studies, we will accelerate the translation of new diagnostic and therapeutic strategies with the potential to have a transformative impact for patients with follicular lymphoma.”
Comments